DexCom (DXCM) – Research Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for DexCom (NASDAQ: DXCM):

  • 10/30/2026 – DexCom had its “strong-buy” rating reaffirmed by Raymond James Financial. They now have a $97.00 price target on the stock, up from $94.00.
  • 10/30/2026 – DexCom had its price target raised by Canaccord Genuity Group from $90.00 to $97.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – DexCom had its price target raised by UBS Group from $102.00 to $107.00. They now have a “buy” rating on the stock.
  • 10/30/2026 – DexCom had its price target raised by JPMorgan Chase & Co. from $82.00 to $85.00. They now have a “neutral” rating on the stock.
  • 10/30/2026 – DexCom had its price target raised by Barclays from $115.00 to $120.00. They now have an “overweight” rating on the stock.
  • 10/26/2026 – DexCom had its price target lowered by Leerink Partners from $94.00 to $87.00. They now have an “outperform” rating on the stock.
  • 10/13/2026 – DexCom was given a new $100.00 price target by Mizuho.
  • 10/12/2026 – DexCom had its price target raised by BTIG Research from $90.00 to $96.00. They now have a “buy” rating on the stock.
  • 10/7/2026 – DexCom had its price target raised by Evercore from $90.00 to $110.00. They now have an “outperform” rating on the stock.
  • 10/7/2026 – DexCom was upgraded by Barclays to “strong-buy”.
  • 10/6/2026 – DexCom is now covered by Barclays. They set an “overweight” rating and a $115.00 price target on the stock.
  • 10/6/2026 – DexCom was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
  • 10/1/2026 – DexCom had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $105.00 price target on the stock, up from $90.00.

DexCom Trading Down 2.8%

NASDAQ DXCM opened at $80.19 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.40 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $29.91 billion, a PE ratio of 31.45, a P/E/G ratio of 1.36 and a beta of 1.45. The stock has a 50-day simple moving average of $84.01 and a 200 day simple moving average of $75.38. DexCom, Inc. has a 12 month low of $56.72 and a 12 month high of $92.59.

DexCom (NASDAQ:DXCM – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.05. The business had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 37.77%. DexCom’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period last year, the company posted $0.61 EPS. Research analysts forecast that DexCom, Inc. will post 2.68 EPS for the current year.

Insiders Place Their Bets

In related news, Director Nicholas Augustinos sold 6,539 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total transaction of $549,537.56. Following the sale, the director directly owned 29,293 shares in the company, valued at $2,461,783.72. This trade represents a 18.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $78.62, for a total value of $201,660.30. Following the completion of the sale, the executive vice president directly owned 120,913 shares in the company, valued at $9,506,180.06. This represents a 2.08% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,822 shares of company stock valued at $1,920,193 over the last ninety days. 0.28% of the stock is owned by insiders.

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.

Read More

Receive News & Ratings for DexCom Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc and related companies with MarketBeat.com's FREE daily email newsletter.